Endomatic
Endovascular Left Atrial Appendage Closure Device
Health Tech & Life Sciences
Private
Company Overview
Snapshot
Founded in June 2018 by Boaz Schwarz, Endomatic operates with 1–10 employees. The company has raised $1 million across four funding rounds from one investor.
Business overview
Endomatic is a Health Tech & Life Sciences company focused on developing a breakthrough endovascular Left Atrial Appendage (LAA) closure device to prevent strokes. The company's core technology aims to eliminate the risk of device-related thrombus (DRT), a significant concern in current LAA occlusion procedures. Endomatic serves the healthcare industry, specifically targeting interventional cardiologists and electrophysiologists, and operates within the Medical Devices and Medical Treatment & Therapeutics sectors.
Log in to access full profile ›Company Intelligence Q&A
- What is Endomatic's primary focus?
- Endomatic is focused on developing an endovascular Left Atrial Appendage (LAA) closure device to prevent strokes, particularly in patients with Atrial Fibrillation.
- Who founded Endomatic?
- Endomatic was founded by Boaz Schwarz in June 2018.
- What is the key innovation of Endomatic's technology?
- Endomatic's patented technology aims to eliminate the risk of device-related thrombus (DRT), a common concern with existing LAA closure devices, due to its non-thrombogenic nature.